Organon (OGN) said Monday it finalized the acquisition of Dermavant Sciences from Roivant (ROIV).

Dermavant develops and commercializes treatments in the immuno-dermatology space, including Vtama, which was approved by the US Food and Drug Administration to treat plaque psoriasis in adults, Organon said.

Price: 17.37, Change: +0.21, Percent Change: +1.22